CovidResearchTrials by Shray Alag


CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)


Anti SARS-CoV 2 Convalescent Plasma in severe COVID-19 patientsWiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (1)


Name (Synonyms) Correlation
drug179 Anti SARS-CoV 2 Convalescent Plasma in critical COVID-19 patients Wiki 1.00

Correlated MeSH Terms (1)


Name (Synonyms) Correlation
D011014 Pneumonia NIH 0.06

Correlated HPO Terms (1)


Name (Synonyms) Correlation
HP:0002090 Pneumonia HPO 0.06

There is one clinical trial.

Clinical Trials


1 Treatment of Severe and Critical COVID-19 Pneumonia With Convalescent Plasma

Open label two arms, non randomized Convalescent Plasma treatment to severe and critical pneumonia COVID-19 hospitlaized patients compared to a historical cohort with matched controls.

NCT04432103 Covid-19 Biological: Anti SARS-CoV 2 Convalescent Plasma in severe COVID-19 patients Biological: Anti SARS-CoV 2 Convalescent Plasma in critical COVID-19 patients
MeSH:Pneumonia
HPO:Pneumonia

Primary Outcomes

Description: progression to critical stage

Measure: INCIDENCE OF CRITICAL PNEUMONIA

Time: 14 days after convalescent plasma administration

Description: mortality

Measure: MORTALITY RATE AMONG CRITICAL PNEUMONIA PATIENTS

Time: 28 days after convalescent plasma administration

Secondary Outcomes

Description: time to need mechanical ventilation

Measure: INCIDENCE OF MECHANICAL VENTILATION

Time: 14 days after convalescent plasma treatment

Description: time of mechanical ventilation needed

Measure: DAYS OF MECHANICAL VENTILATION

Time: 28 days after convalescent plasma treatment


Related HPO nodes (Using clinical trials)